Clinical trials: Lymphomas,
T-cell Lymphoblastic Lymphoma
Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
T-cell lymphoblastic lymphoma (T-LBL) is the second most common subtype of non-Hodgkin lymphoma (NHL) in children and adolescents. With current treatment, event-free survival (EFS) rates vary between 75%~85%.
- Trial name
- NCT05681260
- Testing
- Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Children's Cancer Group, China
Extranodal NK/T-cell Lymphoma, Nasal Type
Multi-omics Profiling of Relapsed Extranodal Natural Killer (NK)/T-cell Lymphoma
This retrospective observational study characterises the tumour immune microenvironment and clonal architecture of relapsed or refractory extranodal NK/T-cell lymphoma (ENKTCL).
- Trial name
- NCT07920757
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University Union Hospital
Gastric Diffuse Large B-cell Lymphoma
First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL
Aims: A nationwide study to prospectively validate 1. The complete histological and molecular remission rate for antibiotics as 1st-line therapy for early-stage Hp-positive gastric pure (de novo) DLBCL 2.
- Trial name
- NCT02388581
- Testing
- Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Health Research Institutes, Taiwan
Acute T Cell Leukemia
Ruxolitinib Plus LVP in Patients With R/R ETP-ALL
To determine the maximum tolerated dose (MTD), if present, and dose schedule of ruxolitinib in combination with L-ASP, vincristine, and prednisone (LVP) in patients with relapsed-and-refractory (R/R) early T precursor acute…
- Trial name
- NCT03613428
- Testing
- Ruxolitinib, Vincristine, Prednisone
- Volunteers
- 12 people
- Sponsor
- Sichuan University
Anaplastic Large Cell Lymphoma, ALK-Positive
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of overall survival.
- Trial name
- ACCELERATE (NCT07013565)
- Testing
- Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
Pediatric ALL
Effectiveness of Developed Interactive Play Mat In Pediatric Physical Therapy
The proposed study seeks to innovate by harnessing the potential of an interactive play mat, integrating haptic feedback and captivating sensory stimuli, to facilitate and expedite the motor skill development process in children…
- Trial name
- NCT06654583
- Testing
- Interactive Play Mat, Conventional Physical Therapy
- Where
- Pakistan
- Volunteers
- 54 people
- Sponsor
- Superior University
Hodgkin Disease
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen…
- Trial name
- NCT02979522
- Testing
- Brentuximab vedotin, Doxorubicin, Vinblastine
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 59 people
- Sponsor
- Takeda
B Cell Precursor Acute Lymphoblastic Leukemia
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL), to…
- Trial name
- NCT04521231
- Testing
- Blinatumomab
- Where
- 109 sites in United States, Argentina and 18 more
- Volunteers
- 181 people
- Sponsor
- Amgen
Lymphoma
Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00004907
- Testing
- busulfan, cyclophosphamide, etoposide
- Where
- United States
- Sponsor
- Northwestern University
Non Hodgkin Lymphoma, Richter Transformation
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing…
- Conditions
- Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia
- Trial name
- NCT04771572
- Testing
- LP-118
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newave Pharmaceutical Inc
Hematologic Malignancy
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
Participants in this study have a hematologic malignancy (a disorder in the bone marrow that affects the body's ability to create blood) that might benefit from receiving an allogeneic stem cell transplant (meaning the cells come…
- Trial name
- NCT00056966
- Testing
- ANTI-CD45, CAMPATH-1H, FK506
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Baylor College of Medicine
Lymphoma, HIV
Autologous Transplant in HIV Patients (BMT CTN 0803)
This study is a Phase II, multicenter trial assessing overall survival after autologous hematopoietic stem cell transplantation using a BEAM transplant regimen (carmustine, etoposide, cytarabine, melphalan) in lymphoma patients…
- Trial name
- NCT01141712
- Testing
- Autologous transplant, BCNU, Etoposide
- Where
- 16 sites in United States
- Volunteers
- 43 people
- Sponsor
- Medical College of Wisconsin
Induction Chemotherapy, Acute T-Lymphocytic Leukemia
Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients
The purpose of this study is to evaluate the efficacy and safety of decitabine combined with HAAG regimen in the treatment of newly diagnosed patients with ETP-ALL/LBL, T/M-MPAL and ALL/LBL with myeloid or stem cell markers.
- Conditions
- Induction Chemotherapy, Acute T-Lymphocytic Leukemia, T-cell Lymphoblastic Lymphoma Leukemia, T-cell/Myeloid Mixed Phenotype Acute Leukemia
- Trial name
- NCT04446130
- Testing
- Decitabine combined with HAAG Regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)
- Trial name
- NCT03185494
- Testing
- anti-CD19/22-CAR vector-transduced T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Hodgkin's Disease, Leukemia
Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT
The purpose of this study is to determine if we can prevent Epstein Barr Virus lymphomas by the monthly administration of an (antibody) protein against B lymphocytes called Rituximab.
- Conditions
- Hodgkin's Disease, Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT00648037
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed Pediatric ALL, Hematopoietic Cell Transplantation
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-risk CD19 positive leukemia ALL.
- Conditions
- Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy
- Trial name
- NCT07257419
- Testing
- Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- St. Jude Children's Research Hospital
Adult Hodgkin Lymphoma, Adult Myelodysplastic Syndrome
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
This pilot phase I/II trial studies the side effects and how well sirolimus and mycophenolate mofetil work in preventing graft versus host disease (GvHD) in patients with hematologic malignancies undergoing hematopoietic stem…
- Conditions
- Adult Hodgkin Lymphoma, Adult Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT02728700
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Stanford University
Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia
Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML
This is a Phase I, multi-center, open-label, dose escalation, MTD study of liposomal annamycin in children and young adults with refractory or relapsed ALL or AML.
- Trial name
- NCT00430443
- Testing
- Liposomal Annamycin
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Callisto Pharmaceuticals
Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia (ALL)
Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor…
- Trial name
- NCT06392763
- Where
- France
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphoma
Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation
The National Marrow Donor Program (NMDP) has established a system for registering, matching, and tracking unrelated donor cord blood units (CBUs) and transplant outcomes.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00737516
- Testing
- HPC, Cord Blood
- Where
- 19 sites in United States
- Volunteers
- 3,621 people, healthy volunteers welcome
- Sponsor
- National Marrow Donor Program
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.